Prediabetes
Research Summary
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes
Moderate confidence
Low bias
Last updated May 16, 2026Key Takeaway:
Newer drugs like semaglutide and tirzepatide appear best for weight and blood sugar in prediabetes.
Study at a Glance
What was studied
55 studies with 16,610 adults with prediabetes testing nine medication types over 3 months to 2+ years
Study Type
Meta-Analysis
duration
Long-Term (> 12 mo)
Intervention
Semaglutide, Tirzepatide, Liraglutide, Pioglitazone, Metformin, Dapagliflozin
Outcomes
Body weight, HbA1c, BMI, (no title), Total cholesterol, Triglycerides, Renal and urinary disorders incidence
Funding
Non-Industry Sponsored
Save this study and add notes to your research library.
Main Effects
Weight → ↓ (strong with semaglutide, tirzepatide)
HbA1c → ↓ (moderate with most drugs)
Cholesterol → ↓ (moderate with tirzepatide, pioglitazone)
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Dapagliflozin (Medications) |  Body weight (Weight & Anthropometrics) | Decrease | Limited |
Dapagliflozin (Medications) |  HbA1c (Glycemic Control) | Decrease | Limited |
Dapagliflozin (Medications) |  Renal and urinary disorders incidence (Safety) | Decrease | Strong |
Liraglutide (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Limited |
Liraglutide (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Metformin (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Limited |
Metformin (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Pioglitazone (Medications) | Body weight (Weight & Anthropometrics) | Increase | Limited |
Pioglitazone (Medications) |  Triglycerides (Metabolic Health) | Decrease | Strong |
Semaglutide (Medications) | BMI (Weight & Anthropometrics) | Decrease | Strong |
Semaglutide (Medications) | Body weight (Weight & Anthropometrics) | Decrease | Strong |
Semaglutide (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Tirzepatide (Medications) | BMI (Weight & Anthropometrics) | Decrease | Strong |
Tirzepatide (Medications) | Total cholesterol (Metabolic Health) | Decrease | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Newer medications like semaglutide and tirzepatide appear to offer the best combined benefits for weight loss and blood sugar control in people with prediabetes who are overweight
- Older medications like pioglitazone lower blood sugar effectively but cause weight gain, which limits their usefulness
- Effects vary by medication type, with no single drug working best for all outcomes
Who this applies to
Adults aged 18-75 with prediabetes based on blood tests showing HbA1c of 5.7-6.4% or elevated fasting blood sugar
Keep in Mind
Most studies compared drugs to placebo rather than directly to each other, so we can't be certain which drug works best
Between the Lines
- Most studies compared to placebo, not to each other
- Results varied widely between studies
- Study lengths ranged from 3 months to 2+ years
- Most participants were of European ancestry
Journal Reference
Wu Y, Wang Z, Tuersun A, et al. Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis. BMC Med. 2026;24:174. doi:10.1186/s12916-026-04705-2
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, SGLT2 Inhibitors and Adverse Events.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
2 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Adverse Events Evidence Hub
All studies measuring Adverse Events
1 studies
outcome_hubMeasures Adverse Events as a key outcome.
Lipid Profile Evidence Hub
All studies measuring Lipid Profile
1 studies
outcome_hubMeasures Lipid Profile as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
1 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
2 results
All studies on Dapagliflozin and Renal and urinary disorders incidence
Intervention: DapagliflozinOutcome: Renal and urinary disorders incidence
1 results
All studies on Semaglutide
Intervention: Semaglutide
2 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
1 results
All studies measuring Body weight
Outcome: Body weight
2 results
Questions this evidence helps answer
Key clinical and research questions this study contributes to.
Does semaglutide improve Body weight?
Based on connected evidence for Semaglutide and Body weight.
Does dapagliflozin affect Renal and urinary disorders incidence in people with diabetes?
Exploring evidence on Dapagliflozin and Renal and urinary disorders incidence outcomes.
What does the evidence say about tirzepatide and Total cholesterol?
Review of studies examining Tirzepatide and Total cholesterol.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.